Date: 2017-05-22
Type of information: Research agreement
Compound: undisclosed novel protein therapeutic for the treatment of neurodegenerative diseases and neuroinflammation.
Company: AC Immune (Switzerland) Essex Bio-Technology (China)
Therapeutic area: Neurodegenerative diseases
Type agreement: research - R&D
Action mechanism: protein.
Disease: Neurodegenerative diseases, neuroinflammation.
Details:
- • On May 22, 2017, AC Immune and Essex Bio-Technology Limited announced that they have entered into a research collaboration agreement to undertake the pre-clinical and clinical co-development of a novel biological therapeutic for the treatment of neurodegenerative diseases and neuroinflammation.
This agreement gives AC Immune its first R&D base in Asia with potential new development opportunities in that region.
The initial objective for the collaboration is the development of a recombinant protein therapeutic candidate acting on a unique neuroprotective mechanism for treatment of neurological diseases, such as Alzheimer’s disease and frontotemporal dementia. Essex will provide joint research commitment as well as financial support to AC Immune for the pre-IND development of the biological agent. The two companies will pursue a joint clinical development and commercial strategy for a potential product.
Financial terms:
- Specific timelines and financial terms were not disclosed.
Latest news:
Is general: Yes
